|
Powered by Cell Signaling Technology |
|
Powered by Cell Signaling Technology |
| Site Information |
|---|
| NRPLLRNsLDDLVGP SwissProt Entrez-Gene |
| Blast this site against: NCBI SwissProt PDB |
| Site Group ID: 4252802 |
| In vivo Characterization | |
|---|---|
| Methods used to characterize site in vivo: | |
| Disease tissue studied: | |
| Relevant cell line - cell type - tissue: | |
| Upstream Regulation | |
|---|---|
| Putative in vivo kinases: | |
| Treatments: | |
| Downstream Regulation | |
|---|---|
| Effects of modification on SRC-3: | |
| Inhibit interaction with: | |
| References | |
|---|---|
|
Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275 Curated Info |
|
|
Sacco F, et al. (2016) Deep Proteomics of Breast Cancer Cells Reveals that Metformin Rewires Signaling Networks Away from a Pro-growth State. Cell Syst 2, 159-71
27135362 Curated Info |
|
|
Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62
24275569 Curated Info |
|
|
Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163 Curated Info |
|
|
Yi P, et al. (2008) Atypical protein kinase C regulates dual pathways for degradation of the oncogenic coactivator SRC-3/AIB1. Mol Cell 29, 465-76
18313384 Curated Info |
